Academic Journal
Q1Haematologica
About Haematologica
Haematologica is a scholarly journal published by Ferrata Storti Foundation. SCImago 2025 lists it in Q1, with an SJR of 2.534 and H-index of 179.
Coverage: 1947-2026. Research categories: Hematology (Q1).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
Avatrombopag as a novel salvage therapy for refractory thrombocytopenia in <i>THPO</i>-mutated congenital amegakaryocytic thrombocytopenia after allogeneic hematopoietic stem cell transplantation
Ji-Mo Jian, Zi-Jing Ye, Hong-Yuan Hao, Cheng-Lu Yuan et al.
2026-09-17 · DOI: 10.3324/haematol.2026.301304Phenotype-directed allele-specific flow cytometry identifies HLA-loss relapse after haploidentical hematopoietic cell transplantation for adult T-cell leukemia/lymphoma
Takumi Kimura, Yoshitaka Zaimoku, Hayato Kawashima, Shinya Yamada et al.
2026-09-17 · DOI: 10.3324/haematol.2026.301574Are all risk factors created equal in multiple myeloma?
Sina A. Beer, Martin F. Kaiser
2026-09-17 · DOI: 10.3324/haematol.2026.301908Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis
Andrew J. Cowan, Luuk Gras, Raffaella Cassano, Yoshiko Atsuta et al.
2026-09-17 · DOI: 10.3324/haematol.2026.301244Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era
Zainab Shahid, Judy Yan, Sigrun Einarsdottir, Shauna Usiak et al.
2026-09-17 · DOI: 10.3324/haematol.2026.300744Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”
Tang-Her Jaing, Yi-Lun Wang
2026-09-17 · DOI: 10.3324/haematol.2026.301889Autoimmune hemolytic anemia and chronic lymphocytic leukemia: crossing the borders between autoimmunity and malignancy
Marta Coscia, Luca Arcaini
2026-09-17 · DOI: 10.3324/haematol.2026.301716Protecting sickle cell care during Ebola outbreaks
Serge Tonen-Wolyec
2026-09-17 · DOI: 10.3324/haematol.2026.301925T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?
Federico Stella, Joseph A. Fraietta, Stephen J. Schuster, Marco Ruella et al.
2026-09-17 · DOI: 10.3324/haematol.2026.301592Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia
Emilia Cappello, Marco Lucioni, Emanuela Boveri, Virginia V. Ferretti et al.
2026-09-17 · DOI: 10.3324/haematol.2025.300113Multiparametric flow-cytometry minimal residual disease before hematopoietic stem cell transplantation predicts outcome in pediatric acute myeloid leukemia
Barbara Buldini, Pietro Merli, Elena Varotto, Riccardo Masetti et al.
2026-09-17 · DOI: 10.3324/haematol.2026.300844Procoagulant platelets in haemostasis and thrombosis
Siyu Sun, Rainer Kaiser, Johan W.M. Heemskerk, Leo Nicolai et al.
2026-09-17 · DOI: 10.3324/haematol.2026.301360Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population
Aisling Barrett, Zhe Wang, Paul McGale, John Broggio et al.
2026-09-10 · DOI: 10.3324/haematol.2026.301079Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”
Shigeru Kusumoto, Takayoshi Tachibana
2026-09-10 · DOI: 10.3324/haematol.2026.301865First line asciminib in chronic myeloid leukemia: a quest for the “Holy Grail” of tolerability.
Delphine Rea
2026-09-10 · DOI: 10.3324/haematol.2026.301753Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study
Tamir Shragai, Noa Lavi, Iuliana Vaxman, Moshe E. Gatt et al.
2026-09-10 · DOI: 10.3324/haematol.2026.301067Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma
Rebekka J.S. Salzmann, Caterina Elia, Elisa Carraro, Marta Pillon et al.
2026-09-10 · DOI: 10.3324/haematol.2026.301490Successful treatment of systemic juvenile xanthogranuloma with an <i>ABL2::GAB2</i> fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition
Juanjuan Li, Mei Yue, Yuchun Yan, Lei Zhang et al.
2026-09-10 · DOI: 10.3324/haematol.2026.301552“Bendamustine monotherapy induces high response rates and STAT3 inhibition in high burden T-cell large granular lymphocytic leukemia”
Luca Massarotti, Elisa Rampazzo, Giulia Calabretto, Laura Pavan et al.
2026-09-10 · DOI: 10.3324/haematol.2026.300962Progressive hematopoietic stem cell mobilization during human pregnancy is associated with cholesterol metabolism
Christine C. Nkemeh, Brandon L. Vu, Itaevia M. Curry-Chisolm, Shontreal M. Cooper et al.
2026-09-10 · DOI: 10.3324/haematol.2026.301400Reviews
Community Reviews
Version History
September 19, 2026 at 2:15 am
September 19, 2026